| Range: | 4.71-9.74 | Vol Avg: | 1237223 | Last Div: | 0 | Changes: | 0.09 |
| Beta: | 1.46 | Cap: | 1.27B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Sep 03 2014 | Empoloyees: | 300 | ||
| CUSIP: | 05156V102 | CIK: | 0001600620 | ISIN: | CA05156V1022 | Country: | CA |
| CEO: | Mr. Peter S. Greenleaf M.B.A. | Website: | https://www.auriniapharma.com | ||||
AUPH 9.00 Stock Price Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Stock Details
Positive 0.47
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:...
businesswire.com·Fri Nov 15 2024
Neutral 0.00
Aurinia to Participate in Jefferies London Healthcare Conference
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in Jefferies L...
businesswire.com·Thu Nov 14 2024
Positive 0.44
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
Today, we are following up on biopharma name Aurinia Pharmaceuticals Inc. The company just...
seekingalpha.com·Fri Nov 08 2024
Positive 0.28
Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript
Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH ) Q3 2024 Earnings Conference Call November 7, ...
seekingalpha.com·Thu Nov 07 2024
Positive 0.20
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Presents New Data Highlightin...
businesswire.com·Fri Oct 11 2024
Positive 0.25
3 Small Biotech Stocks With The 'Big Mo' Right Now
Three small biotech stocks that I have covered lately have shown significant upward moveme...
seekingalpha.com·Thu Sep 19 2024
Positive 0.30
Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment
Aurinia Pharmaceuticals' LUPKYNIS, an FDA-approved treatment for lupus nephritis, is well-...
seekingalpha.com·Thu Sep 19 2024
Positive 0.11
Aurinia Pharmaceuticals: This Recovery Can Continue
Aurinia Pharmaceuticals shows promising growth with increased Lupkynis sales. The near fut...
seekingalpha.com·Wed Sep 18 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow